Yuan Yanhong, Wang Qin, Ni Zhaohui, Che Xiajing, Cao Liou, Shao Xinghua, Zhang Minfang, Xie Yuanyuan, Qi Chaojun, Zhou Wenyan, Tian Lei, Mou Shan
Department of Nephrology, Molecular Cell Lab for Kidney Disease, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, 160 Pujian Road, Shanghai, 200127, China.
J Transl Med. 2015 Jun 6;13:186. doi: 10.1186/s12967-015-0549-2.
Corticosteroids are preferred to treat patients with active IgA nephropathy (IgAN), and beneficial effects from the short-term use of corticosteroids have been confirmed. However, a large number of patients will progress to end-stage renal disease after a long time follow-up. This study aimed to evaluate kidney disease progression and risk factors on kidney survival in IgAN patients receiving steroids treatment.
Two hundred biopsy-proven IgAN patients who received corticosteroid therapy were enrolled and followed for a median period of 63.33 months. Risk factors on kidney survival were retrospectively investigated by the Cox proportional hazards model.
Of the two hundred patients, twenty patients showed progression of renal impairment at the end of follow-up. The median and interquartile range values for initial serum creatinine were 89.2 and 68.08-121.35 µmol/L, respectively. Multivariate Cox regression analyses revealed that relapse, non-remission, time-averaged eGFR (TA-eGFR), and time-averaged serum albumin (TA-ALB) were independently associated with the kidney progression. Those with TA-ALB levels <35 g/L and TA-eGFR levels <60 mL/min/1.73 m(2) were less likely to recover from kidney progression. Patients were more likely to show kidney function deterioration, when they had non-remission or relapse after corticosteroids treatment.
This study demonstrated that relapse, non-remission, TA-eGFR, and TA-ALB could serve as independent predictors of long term prognosis of IgAN patients receiving corticosteroid therapy.
皮质类固醇是治疗活动性IgA肾病(IgAN)患者的首选药物,短期使用皮质类固醇的有益效果已得到证实。然而,大量患者在长期随访后会进展至终末期肾病。本研究旨在评估接受类固醇治疗的IgAN患者的肾病进展情况及肾脏存活的危险因素。
纳入200例经活检证实接受皮质类固醇治疗的IgAN患者,中位随访时间为63.33个月。通过Cox比例风险模型回顾性研究肾脏存活的危险因素。
200例患者中,20例在随访结束时出现肾功能损害进展。初始血清肌酐的中位数和四分位数间距值分别为89.2和68.08 - 121.35µmol/L。多变量Cox回归分析显示,复发、未缓解、时间平均估算肾小球滤过率(TA - eGFR)和时间平均血清白蛋白(TA - ALB)与肾脏进展独立相关。TA - ALB水平<35g/L且TA - eGFR水平<60mL/min/1.73m²的患者从肾脏进展中恢复的可能性较小。接受皮质类固醇治疗后未缓解或复发的患者更有可能出现肾功能恶化。
本研究表明,复发、未缓解、TA - eGFR和TA - ALB可作为接受皮质类固醇治疗的IgAN患者长期预后的独立预测指标。